Suche klinische Studie
Weitere Suchoptionen
22 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Abgeschlossene Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; ERN-Mitglied = 
Nationale klinische Studie(n)
DEUTSCHLAND
Bayern
WÜRZBURG
ACSPIRE: SPI-62 zur Behandlung von Hyperkortisolismus aufgrund eines gutartigen Nebennierentumors
Zentrum Innere Medizin (ZIM)
Medizinische Klinik und Poliklinik I - Endokrinologie und Diabetologie
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
ACSPIRE: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor -FR
Institution: Information not provided - FR
ITALIEN
TOSCANA
PISA
ACSPIRE: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor - IT
Azienda Ospedaliero Universitaria Pisana - Ospedale Cisanello
U.O. Endocrinologia 2
NIEDERLANDE
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome (Phase II-III) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
GRADIENT: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant - AT
Institution: Information not provided - AT
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease - BE
Universitair Ziekenhuis Brussel
Endocrinologie
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome (Phase III) - FR
Institution: Information not provided - FR
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
An open label study to asses the safety and efficacy of COR-003 (2S, 4R-Ketoconazole) in the treatment of endogenous Cushing's syndrome (phase III) - IT
Institution: Information not provided - IT
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma - IT
Institution: Information not provided - IT
ITALIEN
LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat (Phase 2) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
GRACE: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome: A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant - AT
Institution: Information not provided - AT
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
GRACE: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome: A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
GRADIENT: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant -ES
Institution: Information not provided - ES
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Institution: Information not provided - US
Multinationale klinische Studie(n)
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
ACSPIRE: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor.
Institution: Information not provided - US
SCHWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
An open label study to asses the safety and efficacy of COR-003 (2S, 4R-Ketoconazole) in the treatment of endogenous Cushing's syndrome (phase III)
Institution: Information not provided - SE
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An open-label, multi-center, roll-over study to assess long term safety inpatients with endogenous Cushingâ??s syndrome who have completed a priorNovartis-sponsored osilodrostat (LCI699) study and are judged by theinvestigator to benefit from continued treatment with osilodrostat. - NA
Institution: Information not provided - CH
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US